Is there today a place for corticosteroids in the treatment of scleroderma?
Autoimmun Rev
; 18(12): 102403, 2019 Dec.
Article
en En
| MEDLINE
| ID: mdl-31639515
ABSTRACT
In systemic sclerosis (SSc), the use of corticosteroids (CS) is controversial due to their association with scleroderma renal crisis (SRC). However, patients with very early and early disease, characterised by main inflammatory component, may benefit from CS therapy. The aim of this review is to discuss pros and cons of CS treatment in SSc, providing current evidence about the use of CS in SSc. Moreover, we discuss also the underlying pathogenetic mechanisms that may be the background for the potential harms and efficacy of CS in SSc.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Esclerodermia Sistémica
/
Corticoesteroides
Tipo de estudio:
Etiology_studies
Idioma:
En
Revista:
Autoimmun Rev
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2019
Tipo del documento:
Article